English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduOctober 17, 2024 – Groundbreaking results from a clinical trial evaluating a novel treatment for advanced-stage classic Hodgkin lymphoma were published today in the New England Journal of Medicine (NEJM). The study, titled “Nivolumab-AVD in Advanced-Stage Classic Hodgkin Lymphoma,” introduces…
Tag: Hodgkin Lymphoma
In Landmark Study, Immunotherapy Boosts Survival of Advanced Hodgkin Lymphoma
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92 percent, suggesting a new standard therapy for the disease. The New England Journal of Medicine published the innovative clinical trial results this week.
NCCN Releases New Resource to Help Families Understand Pediatric Hodgkin Lymphoma, Part of Award-Winning Patient Information Series
The National Comprehensive Cancer Network (NCCN) today announces the publication of NCCN Guidelines for Patients: Hodgkin Lymphoma in Children.
Investigators Develop Model to Predict Overall Survival in Adults Diagnosed with Advanced Stage Hodgkin Lymphoma
Rutgers Cancer Institute of New Jersey and Tufts Medical Center Collaboration Published in Journal of Clinical Oncology
Family ties: Inherited genetic variants increase risk of Hodgkin lymphoma
Large populations studies have previously demonstrated that Hodgkin lymphoma occurs in families, pointing to a likely genetic predisposition that makes these families more likely to develop this cancer.
Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma
A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago and were published today in the New England Journal of Medicine.
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
Leading Cancer Treatment Recommendations from NCCN Now Available in French, German, Italian, Portuguese, Russian, and Spanish
NCCN Guidelines, containing expert recommendations for cancer care, are available in French, German, Italian, Portuguese, Russian, and Spanish can all be accessed for free at NCCN.org/global or via the free Virtual Library of NCCN Guidelines® App
Excellent Research Results for CAR-T Cell Therapy Against Hodgkin Lymphoma
CAR-T cell therapy, which attacks cancer cells using a person’s reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial.
Building an International Consortium to Enhance Decision Making in Hodgkin Lymphoma
Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.
CAR-T immunotherapy for lymphoma studied at UNC Lineberger receives fast-track designation from FDA
Based on proof-of-concept results from clinical trials at University of North Carolina Lineberger Comprehensive Cancer Center and Baylor College of Medicine, an investigational cellular immunotherapy for Hodgkin lymphoma has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.
Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.
Racial Disparities in Survival Outcomes Shown in Pediatric Hodgkin Lymphoma Patients
In what is believed to be the largest dataset study to date examining the role of race on survival outcome for pediatric patients with Hodgkin lymphoma, investigators at Rutgers Cancer Institute of New Jersey have found that black patients have significantly worse overall survival at five years than white patients when accounting for all available clinical variables.